The current modalities in managing spastic children have some limitations; thus, alternative
therapeutic agents are in need. The purpose of this study is to investigate whether …

Spasticity is one of the most common symptoms presented by neurologic patients. Apart
from surgical management, drug therapy is an important treatment of children suffering from …

Background. Focal spasticity of the gastrocnemius-soleus muscles causes equinus gait in
children with cerebral palsy (CP). Botulinum toxin type A (BTX-A), a neuromuscular blocking …

Botulinum toxin type A can be both safe and effective in relieving spasticity in pediatric
patients with cerebral palsy. In our prospective study, we evaluated the functional effect of …

Wallen M, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin
type A and occupational therapy in the upper limbs of children with cerebral palsy: a …

Botulinum toxin type A (BTX‐A) has been used successfully to manage spasticity in children
with cerebral palsy. Little has been done to evaluate treatment outcome and satisfaction …

Botulinum toxin is a neurotoxin that blocks the synaptic release of acetylcholine from
cholinergic nerve terminals mainly at the neuromuscular junction, resulting in irreversible …

BACKGROUND: There is considerable variability in the amount of response to BTX-A
treatment between and within patients with cerebral palsy (CP). AIMS: The purpose of this …

Evidence is increasing to suggest that botulinum toxin type A (BTX‐A) plays a role in the
management of upper extremity spasticity in the paediatric population. However, little …

This retrospective cohort study reviewed set goals and their outcomes of children and
adolescents with severe cerebral palsy who received botulinum toxin A in 2008 and 2009 …